Chiara Borsotti

Chiara Borsotti

Auto-generated profile, based on publicly available information

Chiara Borsotti

Department of Health Sciences University of Piemonte Orientale Novara Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Current Opinion in Virology
Verified
Journal Article
Closed access
CBChiara Borsotti
Chiara Borsotti
EBEster Borroni
Ester Borroni
Antonia FollenziAntonia Follenzi
Antonia Follenzi

3 November 2021 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
COCristina Olgasi
Cristina Olgasi
CBChiara Borsotti
Chiara Borsotti
SMSimone Merlin
Simone Merlin
TBThorsten Bergmann
Thorsten Bergmann
PBPatrick Bittorf
Patrick Bittorf
Antonia FollenziAntonia Follenzi
Antonia Follenzi
Hemophilia A (HA) is a rare bleeding disorder caused by deficiency/dysfunction of the FVIII protein. As current therapies based on frequent FVIII infusions are not a definitive cure, long-term expression of FVIII in endothelial cells through lentiviral vector (LV)-mediated gene transfer holds the promise of a one-time treatment. Thus, here we sought to determine whether LV-corrected blood outgrowth endothelial cells (BOECs) implanted through a prevascularized medical device (Cell Pouch) would rescue the bleeding phenotype of HA mice. To this end, BOECs from HA patients and healthy donors were isolated, expanded, and transduced with an LV carrying FVIII driven by an endothelial-specific promoter employing GMP-like procedures. FVIII-corrected HA BOECs were either directly transplanted into the peritoneal cavity or injected into a Cell Pouch implanted subcutaneously in NSG-HA mice. In both cases, FVIII secretion was sufficient to improve the mouse bleeding phenotype. Indeed, FVIII-corrected HA BOECs reached a relatively short-term clinically relevant engraftment being detected up to 16 weeks after transplantation, and their genomic integration profile did not show enrichment for oncogenes, confirming the process safety. Overall, this is the first preclinical study showing the safety and feasibility of transplantation of GMP-like produced LV-corrected BOECs within an implantable device for the long-term treatment of HA.

26 May 2022 in Clinical Immunology
Verified
Journal Article
Closed access
AVAndrea Vecchione
Andrea Vecchione
RMRachel Madley
Rachel Madley
NDNichole Danzl
Nichole Danzl
CBChiara Borsotti
Chiara Borsotti
MMMohsen Khosravi Marharlooei
Mohsen Khosravi Marharlooei
MSMegan Sykes
Megan Sykes

12 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ADANNARITA D'URSO
ANNARITA D'URSO
FOFrancesca Oltolina
Francesca Oltolina
CBChiara Borsotti
Chiara Borsotti
MPMaria Prat
Maria Prat
Donato ColangeloDonato Colangelo
Donato Colangelo
Antonia FollenziAntonia Follenzi
Antonia Follenzi
New therapeutic strategies are required in cancer therapy. Considering the prominent role of tumor-associated macrophages (TAMs) in the development and progression of cancer, the re-education of TAMs in the tumor microenvironment (TME) could represent a potential approach for cancer immunotherapy. TAMs display an irregular unfolded protein response (UPR) in their endoplasmic reticulum (ER) to endure environmental stress and ensure anti-cancer immunity. Therefore, nanotechnology could be an attractive tool to modulate the UPR in TAMs, providing an alternative strategy for TAM-targeted repolarization therapy. Herein, we developed and tested polydopamine-coupled magnetite nanoparticles (PDA-MNPs) functionalized with small interfering RNAs (siRNA) to downregulate the protein kinase R (PKR)-like ER kinase (PERK) expression in TAM-like macrophages derived from murine peritoneal exudate (PEMs). After the evaluation of the cytocompatibility, the cellular uptake, and the gene silencing efficiency of PDA-MNPs/siPERK in PEMs, we analyzed their ability to re-polarize in vitro these macrophages from M2 to the M1 inflammatory anti-tumor phenotype. Our results indicate that PDA-MNPs, with their magnetic and immunomodulator features, are cytocompatible and able to re-educate TAMs toward the M1 phenotype by PERK inhibition, a UPR effector contributing to TAM metabolic adaptation. These findings can provide a novel strategy for the development of new tumor immunotherapies in vivo.

21 March 2022 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
GNGrace Nauman
Grace Nauman
NDNichole M. Danzl
Nichole M. Danzl
JLJaeyop Lee
Jaeyop Lee
CBChiara Borsotti
Chiara Borsotti
RMRachel Madley
Rachel Madley
MSMegan Sykes
Megan Sykes
Immunodeficient mice reconstituted with immune systems from patients, or personalized immune (PI) mice, are powerful tools for understanding human disease. Compared with immunodeficient mice transplanted with human fetal thymus tissue and fetal liver–derived CD34+ cells administered i.v. (Hu/Hu mice), PI mice, which are transplanted with human fetal thymus and adult bone marrow (aBM) CD34+ cells, demonstrate reduced levels of human reconstitution. We characterized APC and APC progenitor repopulation in human immune system mice and detected significant reductions in blood, bone marrow (BM), and splenic APC populations in PI compared with Hu/Hu mice. APC progenitors and hematopoietic stem cells (HSCs) were less abundant in aBM CD34+ cells compared with fetal liver–derived CD34+ cell preparations, and this reduction in APC progenitors was reflected in the BM of PI compared with Hu/Hu mice 14–20 wk posttransplant. The number of HSCs increased in PI mice compared with the originally infused BM cells and maintained functional repopulation potential, because BM from some PI mice 28 wk posttransplant generated human myeloid and lymphoid cells in secondary recipients. Moreover, long-term PI mouse BM contained functional T cell progenitors, evidenced by thymopoiesis in thymic organ cultures. Injection of aBM cells directly into the BM cavity, transgenic expression of hematopoietic cytokines, and coinfusion of human BM-derived mesenchymal stem cells synergized to enhance long-term B cell and monocyte levels in PI mice. These improvements allow a sustained time frame of 18–22 wk where APCs and T cells are present and greater flexibility for modeling immune disease pathogenesis and immunotherapies in PI mice.

1 June 2020 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
MEMuhammad Elnaggar
Muhammad Elnaggar
AAAnjud Al-Mohannadi
Anjud Al-Mohannadi
DKDhanya Kizhakayil
Dhanya Kizhakayil
CRChristophe Raynaud
Christophe Raynaud
SASharefa Al-Mannai
Sharefa Al-Mannai
SDSara Deola
Sara Deola
Detection of factor VIII (FVIII) in cells by flow cytometry is controversial, and no monoclonal fluorescent antibody is commercially available. In this study, we optimized such an assay and successfully used it as a platform to study the functional properties of phosphoglycerate kinase (PGK)-FVIII lentiviral vector-transduced cells by directly visualizing FVIII in cells after different gene transfer conditions. We could measure cellular stress parameters after transduction by correlating gene expression and protein accumulation data. Flow cytometry performed on transduced cell lines showed that increasing MOI rates resulted in increased protein levels, plateauing after an MOI of 30. We speculated that, at higher MOI, FVIII production could be impaired by a limiting factor required for proper folding. To test this hypothesis, we interfered with the unfolded protein response by blocking proteasomal degradation and measured the accumulation of intracellular misfolded protein. Interestingly, at higher MOIs the cells displayed signs of toxicity with reactive oxygen species accumulation. This suggests the need for identifying a safe window of transduction dose to avoid consequent cell toxicity. Herein, we show that our flow cytometry platform for intracytoplasmic FVIII protein detection is a reliable method for optimizing gene therapy protocols in hemophilia A by shedding light on the functional status of cells after gene transfer.